Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4313
- Registration Number
- NCT02631057
- Locations
- 🇯🇵
NISED Center, Tokyo, Shinagawa, Japan
🇯🇵1160.254.81001 Boehringer Ingelheim Investigational Site, Shinagawa, Japan
Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 184
- Registration Number
- NCT02629965
- Locations
- 🇯🇵
Tohno Chuo Clinic, Gifu, Mizunami, Japan
🇯🇵Kirigaoka Tsuda Hospital, Fukuoka, Kitakyushu, Japan
🇯🇵Nishi Fukuoka Hospital, Fukuoka, Fukuoka, Japan
To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02629354
- Locations
- 🇿🇦
Boehringer Ingelheim Investigational Site, Bloemfontein, South Africa
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT02624492
- Locations
- 🇪🇸
Hospital La Paz, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Spain
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
All-Case Surveillance of Ofev in Patients With IPF in Japan
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10117
- Registration Number
- NCT02607722
A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT02606877
- Locations
- 🇬🇧
Papworth Hospital, Cambridge, United Kingdom
🇬🇧Glenfield Hospital, Leicester, United Kingdom
🇬🇧Southmead Hospital, Bristol, United Kingdom
Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector
- Conditions
- Healthy
- Interventions
- Drug: BI 695501 prefilled syringeDrug: BI 695501 autoinjector
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 71
- Registration Number
- NCT02606903
- Locations
- 🇧🇪
SGS Belgium NV Research Unit Stuivenberg, Antwerpen, Belgium
Afatinib in NSCLC With HER2 Mutation
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02597946
- Locations
- 🇨🇳
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳The Second Affiliated Hospital to Nanchang University, Nanchang, China
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 580
- Registration Number
- NCT02597933
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇧🇪ULB Hopital Erasme, Bruxelles, Belgium
Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: 14C-BI 409306
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT02597998
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom